Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
PHASE-I TRIAL OF ADOZELESIN USING THE TREATMENT SCHEDULE OF DAILY X 5EVERY 3 WEEKS
Autore:
FOSTER BJ; LORUSSO PM; POPLIN E; ZALUPSKI M; VALDIVIESO M; WOZNIAK A; FLAHERTY L; KASUNIC DA; EARHART RH; BAKER LH;
Indirizzi:
HARPER GRACE HOSP,DIV HEMATOL & ONCOL,ROOM 414,3900 JOHN R DETROIT MI48201 WAYNE STATE UNIV,SCH MED,DEPT INTERNAL MED,DIV HEMATOL & ONCOL DETROIT MI 48201 UPJOHN CO KALAMAZOO MI 49001
Titolo Testata:
Investigational new drugs
fascicolo: 4, volume: 13, anno: 1995,
pagine: 321 - 326
SICI:
0167-6997(1995)13:4<321:PTOAUT>2.0.ZU;2-Q
Fonte:
ISI
Lingua:
ENG
Soggetto:
BIOLOGICAL-ACTIVITY; CC-1065 NSC-298223; DNA; TOXICITY;
Keywords:
DAILY X 5 ADOZELESIN PHASE I;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
16
Recensione:
Indirizzi per estratti:
Citazione:
B.J. Foster et al., "PHASE-I TRIAL OF ADOZELESIN USING THE TREATMENT SCHEDULE OF DAILY X 5EVERY 3 WEEKS", Investigational new drugs, 13(4), 1995, pp. 321-326

Abstract

CC-1065 is a unique alkylating agent that preferentially binds in theminor groove of double-stranded DNA at adenine-thymine-rich sites. Although it has broad antitumor activity in preclinical models its development was discontinued because of deaths observed during preclinical toxicology studies. Adozelesin is a potent synthetic analog that was chosen for clinical development because it had a similar preclinical antitumor spectrum, but did not produce deaths similar to CC-1065 at therapeutic doses. Phase I evaluations using a variety of Adozelesin treatment schedules have been conducted. This report describes our experience using a multiple dose treatment schedule. Endpoints including antitumor response, maximum tolerated dose, dose limiting toxicity as wellas other toxicities and the recommended Phase II starting dose were determined. Adozelesin was given as a 10 minute IV infusion for 5 consecutive days every 21 days or upon recovery from toxicity. The dose range evaluated was 6-30 mcg/m(2)/day. All patients had refractory solid tumors and had received prior cytotoxic treatment. Thirty-three patients (22 men: 11 women) were entered onto the study and 87 courses were initiated. Dose limiting toxicity was cumulative myelosuppression (leucopenia, thrombocytopenia). The maximum tolerated dose was 30 mcg/m(2)/day. The only other significant toxicity was an anaphylactoid syndrome that occurred in 2 patients. A partial response was observed in a patient with refractory soft tissue sarcoma. The recommended Phase II starting dose of Adozelesin using a 10 minute IV infusion for 5 consecutive days is 25 mcg/m(2)/day to be repeated every 4-6 weeks to allow recovery from myelotoxicity, based on our experience. Additional Phase Iand II studies with Adozelesin are recommended.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 02/07/20 alle ore 21:31:06